CO-DIAGNOSTICS INC

CODXNASDAQ

🏆 #5401 by market capEarnings Nov 11US Equity

$437.81▼ $7.79 (−1.78%)

Simulated price

🔔

Track CODX

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 1.8%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$1M

Small Cap

📈Revenue Growth (YoY)

-84.1%

Declining

📊Gross Margin

8.1%

Thin

💵FCF Margin

-3808.0%

Thin

⚖️P/S Ratio

1.7x

Cheap

Otter Score

Fair

No chart data available for CODX.

Trading Snapshot

Day Range: $434.47 – $442.23
52-Week Range: $0.91 – $46.50
Volume: $2.75B
Avg Volume: $2.24B
Shares Outstanding: 1.1M
Next Earnings: Dec 7, 2026

Fundamentals Snapshot

Annual Revenue: $622,489
Last Q Revenue: $166,131
P/E Ratio: -0.0
P/S Ratio: 1.7x
EPS (TTM): $-10.92
Dividend Yield: 0.00%
Dilution (1yr): +20.7%

Why Investors Own CODX

✓High-growth profile — revenue up +42.9% YoY with expanding US Equity exposure.
✓Healthy economics — 65% gross margin and 22% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CO-DIAGNOSTICS INC

CODX

Financial Trends

Revenue

$622K▼ −84.1% YoY

Gross Margin

64.3%▼ −13.7% YoY

Operating Income

−$31M▼ −22.0% YoY

Free Cash Flow

−$30M▼ −0.2% YoY

Shares Outstanding

1.3M▲ +20.7% YoY

Net Cash

$11M▲ +$10M YoY

StockOtter · stockotter.space

About CO-DIAGNOSTICS INC

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

🦦